Valstar

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• For Intravesical Use Only.
• ( 2.1 ) VALSTAR is recommended at a dose of 800 mg administered intravesically once a week for six weeks.
• ( 2.1 ) Delay administration at least two weeks after transurethral resection and/or fulguration.
• ( 2.1 ) Warm VALSTAR slowly to room temperature, but do not heat.
• ( 2.1 ) Use caution when handling and preparing the solution of VALSTAR.
• ( 2.2 )
• 2.1 Recommended Dosing For Intravesical Use Only.
• Do NOT administer by intravenous or intramuscular routes.
• VALSTAR is recommended at a dose of 800 mg administered intravesically once a week for six weeks.
• Delay administration at least two weeks after transurethral resection and/or fulguration [ see Warnings and Precautions ( 5.2 , 5.3 )].
• 2.2 Preparation, Handling, and Administration Handle and dispose of VALSTAR in a manner consistent with other cytotoxic drugs. 1 The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug.
• VALSTAR contains polyoxyl castor oil, which has been known to cause leaching of di(2-ethylhexyl) phthalate (DEHP) a hepatotoxic plasticizer, from polyvinyl chloride (PVC) bags and intravenous tubing.
• VALSTAR should be prepared and stored in glass, polypropylene, or polyolefin containers and tubing.
• It is recommended that non-DEHP containing administration sets, such as those that are polyethylene-lined, be used.
• VALSTAR is a sterile, clear red solution.
• Visually inspect for particulate matter and discoloration prior to administration.
• At temperatures below 4°C (39°F), polyoxyl castor oil may begin to form a waxy precipitate.
• If this happens, the vial should be warmed in the hand until the solution is clear.
• If particulate matter is still seen, do not administer VALSTAR.
• For each instillation, slowly allow four 5 mL vials (200 mg valrubicin/5 mL vial) to warm to room temperature, but do not heat.
• Withdraw 20 mL of VALSTAR from the four vials and dilute with 55 mL of 0.9% Sodium Chloride Injection, USP to provide 75 mL of a diluted VALSTAR solution.
• VALSTAR diluted in 0.9% Sodium Chloride Injection, USP for administration is stable for 12 hours at temperatures up to 25°C (77°F).
• Since compatibility data are not available, do not mix VALSTAR with other drugs.
• Insert a urethral catheter into the patient's bladder under aseptic conditions, drain the bladder, and instill the diluted 75 mL VALSTAR solution slowly via gravity flow over a period of several minutes.
• Withdraw the catheter and retain VALSTAR in the bladder for two hours before voiding.
• At the end of two hours, all patients should void.
• Some patients may be unable to retain the drug for the full two hours.
• Instruct patients to maintain adequate hydration following VALSTAR treatment [see Patient Counseling Information ( 17 )] .

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Quoted from the official label, section “Overdosage”.

Use in children

Safety and effectiveness in pediatric patients have not been established.

Quoted from the official label, section “Pediatric Use”.

Use in older people

• Because carcinoma in situ of the bladder generally occurs in older individuals, 85% of the patients enrolled in the clinical studies of VALSTAR were more than 60 years of age (49% of the patients were more than 70 years of age).
• In the primary efficacy studies, the mean age of the population was 69.5 years.
• There are no specific precautions regarding use of VALSTAR in geriatric patients who are otherwise in good health.

Quoted from the official label, section “Geriatric Use”.

Side effects

• The most frequently reported adverse reactions ( > 5%) after administration of VALSTAR are urinary frequency, dysuria, urinary urgency, bladder spasm, hematuria, bladder pain, urinary incontinence, cystitis, urinary tract infection, nocturia, local burning symptoms, abdominal pain, and nausea.
• ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-462-3636 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
• 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
• The safety of VALSTAR was assessed in 230 patients with transitional cell carcinoma of the bladder, including 205 patients who received multiple weekly doses.
• One hundred seventy-nine of the 205 patients received the approved dose and schedule of 800 mg weekly for multiple weeks.
• Approximately 84% of patients who received intravesical VALSTAR in clinical studies experienced local adverse reactions.
• The local adverse reactions associated with VALSTAR usually occur during or shortly after instillation and resolve within 1 to 7 days after the instillate is removed from the bladder.
• Seven out of 143 patients (5%) who were scheduled to receive six doses of VALSTAR failed to receive all of the planned doses because of the occurrence of local bladder symptoms.
• TABLE 1 displays the frequency of the local adverse reactions at baseline and during treatment among 179 patients who received 800 mg doses of VALSTAR in a multiple-cycle treatment regimen.
• TABLE 1 Local Adverse Reactions Before and During Treatment with VALSTAR (N=179) Adverse Reaction Before Treatment During 6-week Course of Treatment ANY LOCAL BLADDER SYMPTOM 45% 88% Urinary Frequency 30% 61% Dysuria 11% 56% Urinary Urgency 27% 57% Bladder Spasm 3% 31% Hematuria 11% 29% Bladder Pain 6% 28% Urinary Incontinence 7% 22% Cystitis 4% 15% Nocturia 2% 7% Local Burning Symptoms – Procedure Related 0% 5% Urethral Pain 0% 3% Pelvic Pain 1% 1% Hematuria (Gross) 0% 1% TABLE 2 displays the adverse reactions other than local bladder symptoms that occurred in 1% or more of the 230 patients who received at least one dose of VALSTAR in a clinical trial.
• TABLE 2 Systemic Adverse Reactions (≥ 1%) Following Intravesical Administration of VALSTAR (N=230) Body System Preferred Term Body as a Whole Abdominal Pain 5% Asthenia 4% Headache 4% Malaise 4% Back Pain 3% Chest Pain 3% Fever 2% Cardiovascular Vasodilation 2% Digestive Nausea 5% Diarrhea 3% Vomiting 2% Flatulence 1% Hemic and Lymphatic Anemia 2% Metabolic and Nutritional Hyperglycemia 1% Peripheral Edema 1% Musculoskeletal Myalgia 1% Nervous Dizziness 3% Respiratory Pneumonia 1% Skin and Appendages Rash 3% Urogenital Urinary Tract Infection 15% Urinary Retention 4% Hematuria (miscroscopic) 3% Adverse reactions other than local reactions that occurred in less than 1% of the patients who received VALSTAR intravesically in clinical trials are listed below.
• Digestive System:
• Tenesmus Metabolic and Nutritional:
• Nonprotein nitrogen increased Skin and Appendages:
• Pruritus Special Senses:
• Taste loss Urogenital System:
• Local skin irritation, poor urine flow, and urethritis

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

• Risk of Metastatic Bladder Cancer with Delayed Cystectomy Inform patients that VALSTAR has been shown to induce complete responses in only about 1 in 5 patients, and that delaying cystectomy could lead to development of metastatic bladder cancer, which is lethal.
• Discuss the relative risk of cystectomy versus the risk of metastatic bladder cancer [see Clinical Trials ( 14 )] and that the risk increases the longer cystectomy is delayed in the presence of persisting CIS.
• Local Adverse Reactions Before and During Treatment Inform patients that the major acute toxicities from VALSTAR are related to irritable bladder symptoms that may occur during instillation and retention of VALSTAR and for a limited period following voiding [see Adverse Reactions ( 6.1 )] .
• Inform patients that for the first 24 hours following administration, red-tinged urine is typical.
• Advise patients to report prolonged irritable bladder symptoms or prolonged passage of red-colored urine immediately to their physician.
• Instruct patients to maintain adequate hydration following VALSTAR treatment.
• Embryo-Fetal Toxicity Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment with VALSTAR and for 6 months after the last dose.
• Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.5 ), Use in Specific Populations ( 8.1 and 8.3 )] .
• Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VALSTAR and for 3 months after the last dose [see Use in Specific Populations ( 8.3 )] .
• Lactation Advise females not to breastfeed during treatment with VALSTAR and for 2 weeks after the last dose [see Use in Specific Populations ( 8.2 )] .
• Healthcare professionals can telephone Endo (1-800-462-3636) for information on this product.
• Manufactured for:
• Endo USA Malvern, PA 19355 Manufactured by:
• BSP Pharmaceuticals S.p.A Latina Scalo, Italy © 2024 Endo, Inc. or one of its affiliates.
• Revised: 07/2024

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

• FORMS AND STRENGTHS 200 mg/5 mL sterile, clear red, solution in single-use vials for intravesical instillation upon dilution. Injection:
• 200 mg/5 mL in single-use vials ( 3 )

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

• VALSTAR is a sterile, clear red solution in polyoxyl castor oil/dehydrated alcohol, USP, containing 40 mg valrubicin per mL.
• VALSTAR is available in single-use, clear glass vials, individually packaged in the following sizes:
• NDC 67979-001-01 Carton of four 200 mg/5 mL single-use vials Store vials under refrigeration at 2°-8°C (36°-46°F) in the carton.
• DO NOT FREEZE.

Quoted from the official label, section “How Supplied”.

What is in it

• VALSTAR contains valrubicin (N-trifluoroacetyladriamycin-14-valerate), which is a semisynthetic analog of the anthracycline doxorubicin as a cytotoxic agent.
• The chemical name of valrubicin is (2 S - cis )-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L- lyxo -hexopyranosyl]oxyl]-2-naphthacenyl]-2-oxoethylpentanoate.
• Valrubicin is an orange or orange-red powder that is highly lipophilic, soluble in methylene chloride, ethanol, methanol and acetone, and relatively insoluble in water.
• Its chemical formula is C 34 H 36 F 3 NO 13 and its molecular weight is 723.65.
• The chemical structure is shown in FIGURE 1.
• VALSTAR is intended for intravesical administration in the urinary bladder.
• It is supplied as a nonaqueous solution that should be diluted before intravesical administration.
• Each vial of VALSTAR contains 200 mg valrubicin at a concentration of 40 mg/mL in 5 mL of 50% polyoxyl castor oil/50% dehydrated alcohol, USP without preservatives or other additives.
• The solution is sterile and nonpyrogenic.
• FIGURE 1.
• Chemical Structure of Valrubicin

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page